New-onset diabetes and antihypertensive drugs: Implications for renin-angiotensin system blockade

Hong Kong Practitioner

Volumn 26, Issue 12, 2004, Pages 515-519

  Chan, N N ^a   Kong, A P S ^b   Chan, J C N ^b  

^a Qualigenics Diabetes Centre   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; LOSARTAN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAMIPRIL; TELMISARTAN; TEMOCAPRIL; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG USE; FOLLOW UP; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACOLOGICAL BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT;

EID: 14844339683     PISSN: 10273948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995;13:1457-1462.
2. Limura O. Insulin resistance and hypertension in Japanese. Hypertens Res 1996;19(Suppl 1):S1-S8.
3. Chobanian AV, Bakris GL, Black HR. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
4. Guideline committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
5. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-1992.
6. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-640.
7. Reid CM, Wing LM, Graham DH. A new paradigm for funding cardiovascular-outcome research in general practice. The Second Australian National Blood Pressure Study. ANBP2 Management Committee. Med J Aust 1998;169:349-350.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
9. Lasaridis AN, Sarafidis PA. What lies behind the intense criticism of ALLHAT? J Hypertens 2004;22:223-224.
10. Standridge JB. A family physician questions the conclusions from ALLHAT. Am J Hypertens 2004;17:361-365.
11. Vidt DG. ALLHAT says diuretics are better; ANBP2 says ACEs are better - can we resolve the differences? Cleve Clin J Med 2004;71:145-150.
12. Gress TW, Nieto FJ, Shahar E. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-912.
13. Yusuf S, Sleight P, Pogue J. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
14. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611-616.
15. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
16. Julius S, Kjeldsen SE, Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
17. Padwal R, Mamdani M, Alter DA. Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care 2004;27:2458-2463.
18. Chan NN, Tong PC, Kong AP, et al. Antihypertensive therapy and incidence of Type 2 diabetes. Diabetes Care (in press).
19. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999;33:1130-1134.
20. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension and cardiovascular disease. An update. Hypertension 2001;37:1053-1059.
21. Verdecchia P, Reboldi G, Angeli F. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-969.
22. Shiuchi T, Cui TX, Wu L, et al. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002;40:329-334.
23. McCarty MF. ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes. Med Hypotheses 2003;60:779-783.
24. Motley ED, Eguchi K, Gardner C, et al. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha. Hypertension 2003;41(3 Pt 2):775-780.
25. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81.
26. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
27. Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004;44:362-368.
28. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88:4496-4501.
29. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993-1002.
30. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-2057.
31. Teo K, Yusuf S, Anderson C. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61.